Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 24;28(3):434–446. doi: 10.1093/ibd/izab193

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 1. — Anti-TL1A demonstrates target engagement in serum and tissue. A, Serum total TL1A levels were measured at baseline in endoscopic improvement responders (n = 18) and nonresponders (n = 32) and at week 14 in endoscopic improvement responders (n = 18) and nonresponders (n = 29). Serum total TL1A increased post-treatment in both endoscopic improvement responders (P < .001) and nonresponders (P < .001). Serum total TL1A was not significantly different between responders and nonresponders at both pre-treatment (P = .14) and post-treatment (P = .23). B, Tissue TL1A levels were measured at baseline in endoscopic improvement responders (n = 18) and nonresponders (n = 32) and at week 14 in endoscopic improvement responders (n = 16) and nonresponders (n = 30). Tissue TL1A decreased post-treatment in both endoscopic improvement responders (P < .001) and nonresponders (P < .001). Tissue TL1A was significantly different between responders and nonresponders pretreatment (P = .03) and was not significantly different post-treatment (P = 1). The responders and nonresponders with averages and standard errors were intentionally displayed side by side for both serum and tissue TL1A measured pre- and post-treatment to provide easy and clear comparison. Abbreviation: TL1A, tumor necrosis factor-like ligand 1A.